Do Green Shoots At AstraZeneca plc Herald Spring Growth At GlaxoSmithKline plc?

The green shoots of recovery at AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) will take a few more years to blossom, says Harvey Jones

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When Pascal Soriot took over as chief executive at AstraZeneca (LSE: AZN) (NYSE: AZN.US) in 2012 many of its bestselling drugs were careering towards a patent cliff.

Worse, Astra had failed to find replacements, after suffering a string of setbacks with its pipeline of antidepressants, and medicines for diabetes and ovarian cancer. Sales had fallen by a painful £2bn in 2011.

The collapsing share price had left the dividend yield nudging a juicy 6%, but growth prospects remained perilous.

Cliff Edge Stuff

As last week’s Q1 results demonstrate, Soriot is safely steering Astra away from that cliff. Some drugs have inevitably crashed over the edge, notably heartburn blockbuster Nexium, where sales fell 3%, but there have been compensations such as new post-heart attack drug Brilinta, where sales leapt 45%.

AstraZeneca isn’t quite ready to burst into life, with Q1 core operating profit down 4% to £1.8bn. But that was partly due to currency headwinds: it is still up 15% on one year ago.

Soriot remains confident that sales will begin to climb steadily from 2017, when the drugs pipeline starts to flow once more, replenishing dwindling sales from old reliable blockbusters.

Thanks to a series of collaborations and joint projects, it now has 119 drugs in the clinical pipeline.

Growing Pains

Just as the green shoots started poking through at AstraZeneca, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) wilted on Chinese bribery accusations and plunging US vaccination sales.

And unlike AstraZeneca and fellow pharmaceutical company Shire, investors didn’t even have takeover speculation to feed on.

But this is the company I named as my top stock for 2015 because I felt it had serious recovery potential. It has made steady progress since rising 10% year-to-date, marginally ahead of the FTSE 100 at 7.5%.

Glaxo is also menaced by that patent cliff as falling sales of respiratory drug Advair hit revenues, and it battles against pricing pressures in the US and generic competition in Europe.

While cutting costs will save £1 billion over three years, what Glaxo really needs are solid new sources of revenue.

Everything’s Gone Green

Markets have responded warmly to its joint venture with Swiss drugmaker Novartis, which should reduce its reliance on blockbuster drugs, but that won’t show results until 2017 either.

Glaxo can boast 40 new projects in late stage development but again, investors will have to be patient.

The new season growth should eventually come, but it won’t come in spring 2015 or 2016. But at least you can seed your portfolio with Astra’s 3.62% yield and Glaxo’s 5.25% while you wait for the stocks to burst forth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »